Codexis, Inc. (NASDAQ:CDXS) Holdings Increased by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its stake in Codexis, Inc. (NASDAQ:CDXS) by 8.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 220,876 shares of the biotechnology company’s stock after acquiring an additional 17,429 shares during the period. Bank of New York Mellon Corp owned 0.27% of Codexis worth $1,054,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in CDXS. Intech Investment Management LLC acquired a new stake in Codexis in the third quarter worth approximately $66,000. Kingswood Wealth Advisors LLC acquired a new stake in shares of Codexis in the fourth quarter valued at $79,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Codexis in the fourth quarter valued at $82,000. Jackson Square Capital LLC bought a new position in Codexis during the fourth quarter valued at about $210,000. Finally, Inspire Investing LLC acquired a new position in Codexis during the fourth quarter worth about $405,000. 78.54% of the stock is currently owned by institutional investors.

Codexis Price Performance

Shares of NASDAQ CDXS opened at $3.07 on Tuesday. Codexis, Inc. has a twelve month low of $2.43 and a twelve month high of $6.08. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39. The firm has a 50-day moving average of $3.87 and a two-hundred day moving average of $3.95. The company has a market capitalization of $254.31 million, a price-to-earnings ratio of -3.53 and a beta of 2.12.

Codexis (NASDAQ:CDXS) last released its earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.09). The business had revenue of $21.46 million for the quarter, compared to analyst estimates of $27.41 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. As a group, analysts expect that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.